EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Impact of chemotherapy and immunotherapy on survival in pediatric primary diffuse leptomeningeal melanomatosis: a systematic review and pooled survival analysis

Khushi H Shah, Mauricio J Guerrero-Ocampo, Italo G Flecha, Caleigh S Roach, Sima Vazquez, Diego Servián, Victor M Lu

Child's Nervous System · 01.05.2026 · 42 (1)

DOI: 10.1007/s00381-026-07264-2 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Child's Nervous System, online erschienen am 01.05.2026. Verfasst von Khushi H Shah und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL, USA. khs55@med.miami.edu. Hauptthemen laut MEDLINE: Immunotherapy, Survival Rate, Meningeal Neoplasms, Melanoma. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Pediatric primary diffuse leptomeningeal melanomatosis (PDLM) is a rare, aggressive malignancy with no established standard of care. We performed an integrated survival analysis to characterize disease course and identify treatment factors associated with overall survival (OS).

Methods

A systematic literature search of PubMed, Embase, and Scopus (2000–2025) was conducted in accordance with PRISMA guidelines. Eligible studies included patients < 18 years with histopathologically confirmed PDLM per 2021 World Health Organization and Expert Care for Rare Adult Solid Cancers criteria and reported OS and treatment data. Survival was assessed using Kaplan–Meier analyses, with univariable and multivariable Cox proportional hazards regression.

Results

Thirty-three pediatric PDLM cases were identified (57.6% male; median age 10 [IQR 3–14] years). Diagnosis was established via tissue sampling in 72.7%, cerebrospinal fluid cytology in 21.2%, and both in 6.1%. Among 13 patients with molecular testing, 69.2% harbored NRAS mutations. Twenty-four patients (72.7%) received treatment: chemotherapy (70.7%), radiation therapy (41.7%), and immunotherapy (62.5%). Median OS was 5.0 [3.5–7.0] months. On Kaplan–Meier analysis, immunotherapy was associated with improved OS ( p < 0.001), including when combined with radiation ( p = 0.038), chemotherapy ( p = 0.006), or both (p = 0.048). Univariable Cox regression showed immunotherapy to be significantly associated with reduced hazard of death (HR 0.23 [0.10–0.51], p < 0.001). On multivariable analysis, immunotherapy (HR 0.22 [0.10–0.49], p < 0.001) and chemotherapy (HR 0.44 [0.21–0.94], p = 0.035) were independently associated with improved OS.

Conclusion

Pediatric PDLM carries a uniformly poor prognosis. Immunotherapy and chemotherapy were the only treatments independently associated with improved survival, highlighting their central role in management of this rare disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapySurvival RateMeningeal NeoplasmsMelanomaSurvival AnalysisHumansChildMaleFemaleChild, PreschoolAdolescentPrognosis

Stichwörter der Autor:innen

Meningeal melanomatosisPediatricPrimary diffuse leptomeningeal melanomatosisPrimary melanocytic tumors

Autor:innen und Institutionen

  • Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL, USA. khs55@med.miami.edu.
  • Hospital de Clinicás, Universidad Nacional de Asunción, San Lorenzo, Paraguay.
  • Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Department of Neurological Surgery, Hospital General Pediátrico "Niños de Acosta Ñu", San Lorenzo, Paraguay.

Zitieren

APA

Shah, K. H., Guerrero-Ocampo, M. J., Flecha, I. G., Roach, C. S., Vazquez, S., Servián, D., & Lu, V. M. (2026). Impact of chemotherapy and immunotherapy on survival in pediatric primary diffuse leptomeningeal melanomatosis: a systematic review and pooled survival analysis. Child's Nervous System, 42(1). https://doi.org/10.1007/s00381-026-07264-2

Vancouver

Shah KH, Guerrero-Ocampo MJ, Flecha IG, Roach CS, Vazquez S, Servián D, et al. Impact of chemotherapy and immunotherapy on survival in pediatric primary diffuse leptomeningeal melanomatosis: a systematic review and pooled survival analysis. Child's Nervous System. 2026;42(1). doi:10.1007/s00381-026-07264-2

BibTeX
@article{Shah2026,
  author = {Shah, Khushi H and Guerrero-Ocampo, Mauricio J and Flecha, Italo G and Roach, Caleigh S and Vazquez, Sima and Servián, Diego and Lu, Victor M},
  title = {Impact of chemotherapy and immunotherapy on survival in pediatric primary diffuse leptomeningeal melanomatosis: a systematic review and pooled survival analysis},
  journal = {Child's Nervous System},
  year = {2026},
  volume = {42},
  number = {1},
  doi = {10.1007/s00381-026-07264-2}
}
Kostenlos starten →